Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 3
2016 3
2019 1
2020 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline.
Pokorna Z, Jirkovsky E, Hlavackova M, Jansova H, Jirkovska A, Lencova-Popelova O, Brazdova P, Kubes J, Sotakova-Kasparova D, Mazurova Y, Adamcova M, Vostatkova L, Holzerova K, Kolar F, Simunek T, Sterba M. Pokorna Z, et al. Among authors: lencova popelova o. Clin Sci (Lond). 2019 Aug 27;133(16):1827-1844. doi: 10.1042/CS20190139. Print 2019 Aug 30. Clin Sci (Lond). 2019. PMID: 31409729
Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity.
Kollárová-Brázdová P, Jirkovská A, Karabanovich G, Pokorná Z, Bavlovič Piskáčková H, Jirkovský E, Kubeš J, Lenčová-Popelová O, Mazurová Y, Adamcová M, Skalická V, Štěrbová-Kovaříková P, Roh J, Šimůnek T, Štěrba M. Kollárová-Brázdová P, et al. Among authors: lencova popelova o. J Pharmacol Exp Ther. 2020 Jun;373(3):402-415. doi: 10.1124/jpet.119.264580. Epub 2020 Apr 6. J Pharmacol Exp Ther. 2020. PMID: 32253261
Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
Lenčová-Popelová O, Jansová H, Jirkovský E, Bureš J, Jirkovská-Vávrová A, Mazurová Y, Reimerová P, Vostatková L, Adamcová M, Hroch M, Pokorná Z, Kovaříková P, Šimůnek T, Štěrba M. Lenčová-Popelová O, et al. Toxicology. 2016 Nov 30;372:52-63. doi: 10.1016/j.tox.2016.11.002. Epub 2016 Nov 2. Toxicology. 2016. PMID: 27816693
Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
Lenčová-Popelová O, Jirkovský E, Jansová H, Jirkovská-Vávrová A, Vostatková-Tichotová L, Mazurová Y, Adamcová M, Chládek J, Hroch M, Pokorná Z, Geršl V, Šimůnek T, Štěrba M. Lenčová-Popelová O, et al. J Mol Cell Cardiol. 2016 Feb;91:92-103. doi: 10.1016/j.yjmcc.2015.12.021. Epub 2015 Dec 23. J Mol Cell Cardiol. 2016. PMID: 26724189
Corrigendum to: "Proteomic investigation of embryonic rat heart-derived H9c2 cell line sheds new light on the molecular phenotype of the popular cell model" [Exp. Cell Res. 339 2 (2015) 174-186].
Lenčo J, Lenčová-Popelová O, Link M, Jirkovská A, Tambor V, Potůčková E, Stulík J, Šimůnek T, Štěrba M. Lenčo J, et al. Among authors: lencova popelova o. Exp Cell Res. 2016 May 1;343(2):267. doi: 10.1016/j.yexcr.2016.02.007. Epub 2016 Apr 4. Exp Cell Res. 2016. PMID: 27155561 No abstract available.
Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
Jirkovský E, Lenčová-Popelová O, Hroch M, Adamcová M, Mazurová Y, Vávrová J, Mičuda S, Šimůnek T, Geršl V, Štěrba M. Jirkovský E, et al. Among authors: lencova popelova o. Toxicology. 2013 Sep 15;311(3):191-204. doi: 10.1016/j.tox.2013.06.012. Epub 2013 Jul 4. Toxicology. 2013. PMID: 23831762
Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
Bavlovič Piskáčková H, Jansová H, Kubeš J, Karabanovich G, Váňová N, Kollárová-Brázdová P, Melnikova I, Jirkovská A, Lenčová-Popelová O, Chládek J, Roh J, Šimůnek T, Štěrba M, Štěrbová-Kovaříková P. Bavlovič Piskáčková H, et al. Among authors: lencova popelova o. Sci Rep. 2021 Feb 24;11(1):4456. doi: 10.1038/s41598-021-83688-x. Sci Rep. 2021. PMID: 33627707 Free PMC article.